MedKoo Cat#: 555453 | Name: GSK563

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK563 is a potent GVIA iPLA2 inhibitor (XI(50) 0.0000021, IC50 1 nM). GSK563 is 22 000 times more active against GVIA iPLA2 than GIVA cPLA2. It was found to reduce β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes.

Chemical Structure

GSK563
GSK563
CAS#1983928-04-6

Theoretical Analysis

MedKoo Cat#: 555453

Name: GSK563

CAS#: 1983928-04-6

Chemical Formula: C16H22O2

Exact Mass: 246.1620

Molecular Weight: 246.35

Elemental Analysis: C, 78.01; H, 9.00; O, 12.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
GSK563; GSK-563; GSK 563;
IUPAC/Chemical Name
trans-3-(4-Phenylbutyl)-4-propyloxetan-2-one
InChi Key
IAYKBJFWLAKGMR-HUUCEWRRSA-N
InChi Code
InChI=1S/C16H22O2/c1-2-8-15-14(16(17)18-15)12-7-6-11-13-9-4-3-5-10-13/h3-5,9-10,14-15H,2,6-8,11-12H2,1H3/t14-,15-/m1/s1
SMILES Code
O=C1O[C@H](CCC)[C@H]1CCCCC2=CC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Ca2+-independent phospholipase A2 (GVIA iPLA2) has gained increasing interest recently as it has been recognized as a participant in biological processes underlying diabetes development and autoimmune-based neurological disorders. The development of potent GVIA iPLA2 inhibitors is of great importance because only a few have been reported so far.

Preparing Stock Solutions

The following data is based on the product molecular weight 246.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
β-Lactones: A Novel Class of Ca2+-Independent Phospholipase A2 (Group VIA iPLA2) Inhibitors with the Ability To Inhibit β-Cell Apoptosis Christina Dedaki, Maroula G. Kokotou, Varnavas D. Mouchlis, Dimitris Limnios, Xiaoyong Lei, Carol T. Mu, Sasanka Ramanadham, Victoria Magrioti, Edward A. Dennis, and George Kokotos Publication Date (Web): February 23, 2019 (Article) DOI: 10.1021/acs.jmedchem.8b01216